Abstract
Background Previous studies have shown an association between experience of intimate partner violence and abuse (IPVA) and depression. Whether this is a causal relationship or explained by prior vulnerability that influences the risk of both depression and IPVA is not known.
Methods and Findings We analysed data from the Avon Longitudinal Study of Parents and Children prospective cohort (N=1,764 women, 1,028 men). To assess the causal association between IPVA at 18-21 years old and logged depressive symptom scores at age 23, we used: i) multivariable linear regression, ii) inverse probability of treatment weighting (IPTW), and iii) difference-in-difference (DID) analysis, which compared the mean change in logged depressive symptom scores between ages 16 and 23 between those who experienced IPVA and those who did not.
Women who experienced IPVA had on average 26% higher depressive symptom score after adjustment for measured confounders (ratio of geometric means 1.26, 95% CI 1.13 to 1.40). In men, the difference was 5% (ratio of geometric means 1.05, 95% CI 0.92 to 1.21). Results from IPTW analysis were similar. In the DID analysis, there was no evidence that being exposed to IPVA affected the change in depressive symptom scores over time compared to being in the non-exposed group for either women (difference-in-differences: 1%, -12% to 16%) or men (−1%, -19% to 20%).
Conclusions Multivariable linear regression and IPTW suggested an association between IPVA and higher depressive symptom score in women but not men, but DID analysis indicated a null effect in both women and men. This suggests the causal origins of higher depressive symptoms in this young adult population are likely to reflect prior vulnerability that leads to both higher depressive symptoms and increased risk of IPVA exposure.
Key messages
Women and, to a lesser degree, men who experience IPVA between the ages of 18-21 years old tend to have higher levels of depressive symptoms at age 23 years than people who do not.
In women, the association between IPVA and higher depressive symptoms remained after adjustment for measured confounders or use of inverse probability of treatment weighting, whereas in men, the association attenuated to the null after adjustment for measured confounders or use of inverse probability of treatment weighting.
However, the change in depressive symptoms between ages 16 and 23 years was the same in people who experience IPVA and people who did not, for both women and men. This suggests that the higher levels of depressive symptoms in people who experience IPVA is likely to be driven by prior vulnerability that affects the risk of both IPVA exposure and depressive symptoms, highlighting that IPVA is one of a series of challenges being navigated by psychologically vulnerable young adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the UK Medical Research Council (MR/S002634/1). The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grant funding for ALSPAC (PDF, 330KB) is available on the ALSPAC website. This publication is the work of the authors and AH and LDH will serve as guarantors for the contents of this paper. LDH is funded by a Career Development Award from the UK Medical Research Council (MR/M020894/1). AH, JH, AF and LDH work in the MRC Integrative Epidemiology Unit (MC_UU_00011/3).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from the parents of participating children after receiving a full explanation of the study. Children were invited to give assent where appropriate. Study members have the right to withdraw their consent for elements of the study or from the study entirely at any time. Full details of the ALSPAC consent procedures are available on the study website (http://www.bristol.ac.uk/alspac/researchers/research-ethics/). The questions on IPVA were approved by the ALSPAC Ethics and Law Committee (ref: E201210).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
ALSPAC data access is through a system of managed open access. The steps below highlight how to apply for access to ALSPAC data, including access to the Stata/R scripts used for analyses reported in this Research Article.
